Baxter International Inc. (NYSE:BAX) announced that it has entered into a definitive agreement to divest its U.S. generic injectables business to Hikma Pharmaceuticals PLC (LSE:HIK). The consideration for the divestiture arrangement totals approximately $112 million, subject to closing adjustments. The sale of this business will allow Baxter to redirect resources toward its proprietary, enhanced packaging offerings and formulation technologies, consistent with the company's focus on product differentiation...
More...
More...